Collins said he thinks that testing a vaccine in at least 10,000 people could potentially give enough evidence of safety and efficacy to clear it for wider use. The late-stage vaccine trials launched so far in the U.S. aim to recruit up to 30,000 people. (Reporting by Carl O'Donnell in New York and Mrinalika Roy in Bengaluru; Editing by Leslie Adler)
This article is more than 5 years old
Newsdeck
Top U.S. health official says COVID vaccines unlikely to be approved before November
Aug 13 (Reuters) - The potential COVID-19 vaccines backed by the Trump administration's Operation Warp Speed program are unlikely to receive a green light from regulators any earlier than November or December of this year, given the time needed for a large-scale clinical trial, National Institutes of Health director Francis Collins said in a call with reporters on Thursday.
South Africa’s collaboration in clinical trials is not so much about national pride, but rather a ‘national imperative’, says president and CEO of the South African Medical Research Council Dr Glenda Gray.(Photo: trialsitnews.com / Wikipedia)